News zum Sektor Gesundheit aus Asien

 

BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received......

HKEX (00388.HK) announced the results of the semi-annual review of the HKEX Tech 100 Index, adding DEEPEXI TECH (01384.HK), TIME INTERCON (01729.HK), HESAI-W (02525.HK), GEEKPLUS-W (02590.HK), TRANSTHERA-B (02617.HK), CAOCAO INC (02643.HK) and YOFC (06869.HK).Stocks removed from the index include CHINA RUYI (00136.HK), TRAVELSKY......

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four The post Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal appeared first on Pharmaceutical Business review....

FOSUN PHARMA (02196.HK) announced that its innovative oncology immunotherapy FXB0871 has completed dosing of the first participant in a Phase I clinical trial in China (excluding Hong Kong, Macau and Taiwan). FXB0871 is a PD-1-targeted attenuated IL-2 fusion protein immunotherapy (ATTENUKINE) jointly developed by FOSUN PHARMA an......

CSPC PHARMA (01093.HK) announced that Anbenitamab Injection (brand name: Ennituo), co-developed by Shanghai JMT-BIO Technology Co., Ltd., a subsidiary of the Company, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., has received marketing authorisation from the National Medical Products Administration of the People’s Rep......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer schließt eine der größten Biotech-Kooperationen des Jahres ab und setzt dabei auf chinesische Krebsforschung. Was steckt hinter dem 10,5-Milliarden-Deal mit Innovent Biologics? --- Der Deal fällt in eine Phase, in der sich westliche Pharmakonzerne geradezu auf chinesische Biotech-Pipelines stürzen. Das Volumen solcher Lizenzabkommen aus Greater China hat sich laut dem Datenanbieter Pharmcube zwischen 2021 und dem vergangenen Jahr fast verzehnfacht und erreichte 2024 einen Rekordwert von rund 138 Milliarden US-Dollar..

M Stanley issued a research report listing its investment ratings and target prices (TPs) for China biotech stocks as follows:Stock | Investment Rating | TP (HKD)KEYMED BIO-B (02162.HK) | Overweight | HKD93.5 -> HKD97INNOVENT BIO (01801.HK) | Overweight | HKD130 -> HKD135LEADS BIOLABS-B (09887.HK) | Equalweight | HKD59 -&g......

China's Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China's eastern Jiangsu......

Der US-amerikanische Pharma-Riese Pfizer verstärkt seine Entwicklungspipeline. Für bis zu 10,5 Milliarden Dollar sichert sich das Unternehmen die Rechte an zwölf Wirkstoffen der chinesischen Innovent Biologics. Die Aktie der Asiaten gewinnt an der Heimatbörse nach Bekanntwerden des Deals um rund zehn Prozent....

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines....

UBS published a research report stating that TIGERMED (03347.HK) management indicated that operating performance since the beginning of this year has been broadly in line with company guidance, namely achieving a double-digit YoY revenue growth target in 2026 and adjusted net profit of RMB600 million to RMB700 million. As of mid......

FOSUN PHARMA (02196.HK) announced that it officially signed a strategic cooperation framework agreement with GENRIX (688443.SH). The two parties will establish a long-term, stable and mutually trusting strategic partnership to accelerate the research and development and commercialization of innovative drugs, and jointly enhance ......

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOVENT BIO (01801.HK) opened 6.88% higher today, hitting an intraday peak of HKD82.4. It last quoted at HKD80.65, up 7.75%, with a turnover of 5.4011 million shares, involving HKD438 million.INNOVENT BIO announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US) for......

INNOVENT BIO (01801.HK) announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US) for the research and development of 12 promising breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization oppo......

WUXI XDC (02268.HK) announced that, between May 19, 2026 and May 29, 2026, the professional trustee purchased 5.702 million Shares (representing approximately 0.45% of the total number of Shares in issue at the moment) on the open market for an aggregate consideration of approximately HK$327 million, at an average purchase price......

Pfizer Inc. and China's Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer drugs....

SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12......

CHICAGO, May 28, 2026 /PRNewswire/ -- Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has introduced the next generation XR-Series, a hematology solution designed to help busy laboratories......